Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial

By sjmartinez • October 15, 2024

Chew KW, McGinley B, Moser C, Li JZ, Evering TH, Ritz J, Javan AC, Margolis D, Wohl DA, Hughes MD, Daar ES, Currier JS, Eron JJ, Smith DM; ACTIV-2/A5401 Study Team. Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial. J Infect Dis. 2024 Oct 14:jiae501. doi: 10.1093/infdis/jiae501. Epub ahead of print. PMID: 39400063.

Tags: covid-19, COVID-19 treatment, Harbor UCLA, Infectious Diseases, Monoclonal antibodies, non-hospitalized adults, Publications, SARS-CoV-2, symptom rebound, viral rebound

FXYD2 marks and regulates maturity of (beta) cells via ion channel-mediated signal transduction

Tacto C, Tahbaz M, Salib A, Wang S, Cayabyab F, Choi J, Kim K, Hamba Y, Perez H, Gershon PD, Damoiseaux R, Oh TG, Yoshihara[...]

Comparative assessment of CAC and SIS plaque burden categories via AI-guided quantitative CT analysis

Iskander B, Ichikawa K, Punnanithinont N, Kambalapalli S, Kinninger A, Krishnan S, Lakshmanan S, Roy S, Budoff MJ. Comparative assessment of CAC and SIS plaque[...]

Reply: Keto CTA Study

Soto-Mota A, Norwitz NG, Manubolu VS, Kinninger A, Wood TR, Earls J, Feldman D, Budoff M. Reply: Keto CTA Study. JACC Adv. 2025 May 7;4(7):101862.[...]